Revolution Medicines Inc

The KRAS inhibitor market across the seven major markets was valued at approximately $526 million in 2025 and is projected to reach approximately $7.85 billion by 2034, a compound annual growth rate of roughly 35% over its 2024 to 2034 forecast period, according to DelveInsight, with the United States expected to account for nearly 70% of the total. Roots Analysis sizes the category differently, projecting the global KRAS market will grow from approximately $557 million in 2025 to approximately $3.98 billion by 2035, a CAGR of about 21%, and expects intravenously administered therapies to grow faster than the oral drugs that dominate the category today. KRAS mutations account for approximately 85% of RAS-associated cancers in humans, including about 90% of pancreatic cancers, according to Eli Lilly and Company, while in colorectal cancer KRAS mutations appear in approximately 40% of all cases, according to Amgen, yet the G12C subtype targeted by the first approved inhibitors is present in only about 3% to 5% of colorectal cancers. The clinical bar moved sharply in April 2026, when a Phase 3 trial of an oral RAS(ON) multi-selective inhibitor in previously treated metastatic pancreatic cancer reported a median overall survival of 13.2 months versus 6.7 months for chemotherapy, according to the sponsor's SEC filing. Oncolytics Biotech announced positive preclinical results on September 10, 2026 from a study evaluating pelareorep in combination with a pan-RAS inhibitor in a RAS-driven colorectal cancer model, reporting that pelareorep activity was maintained alongside RAS inhibition without evidence of antagonism, though the company said the incremental activity associated with pelareorep became less evident after a transition to less frequent weekly dosing. Oncolytics also said it received written FDA feedback on August 18, 2026 on the design of a potential pivotal Part B expansion of its ongoing REO 033 study in second-line RAS-mutant, microsatellite stable metastatic colorectal cancer, with objective response rate potentially supporting accelerated approval and progression-free survival potentially supporting full approval; the ongoing Part A enrolls 60 patients. Revolution Medicines announced the FDA accepted for review its New Drug Application for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, for previously treated metastatic pancreatic ductal adenocarcinoma, supported by the Phase 3 RASolute 302 trial in which daraxonrasib delivered a median overall survival of 13.2 months versus 6.7 months for chemotherapy with a hazard ratio of 0.40. Amgen reported LUMAKRAS/LUMYKRAS sales up 23% year-over-year to $111 million in its second quarter 2026 results, while total revenues rose 10% to $10.1 billion, and Eli Lilly announced the FDA granted Breakthrough Therapy designation to olomorasib as a monotherapy for adults with advanced pancreatic cancer with a KRAS G12C mutation. Verastem Oncology said it will host an investor event on October 14, 2026 to present initial efficacy and updated safety and tolerability data for VS-7375, its investigational oral KRAS G12D inhibitor, and reported second quarter 2026 net product revenue of $25.1 million for AVMAPKI FAKZYNJA CO-PACK.

Revolution Medicines has received Breakthrough Therapy Designation from the FDA for RASONQUE in treatment-naïve metastatic pancreatic adenocarcinoma, a cancer setting with limited options and intense clinical interest. The regulatory win lands against a mixed stretch for the stock, which eased 5.9% over the past week and 7.9% over the past month, though it still shows a 13.6% three-month share price return and a very large one-year total shareholder return. Revolution Medicines closed at $192.86, while the most followed narrative pegs fair value at $251.21, implying 23% undervaluation. The company has eight ongoing or planned Phase III registrational trials and clinical experience in more than 2,500 patients, with its RAS(ON) portfolio targeting high unmet need tumors including pancreatic, lung and colorectal cancer. Bulls point to its position as an early-stage oncology leader with fresh FDA recognition, while bears focus on zero revenue and heavy losses, and the story could shift quickly if key Phase 3 trials disappoint or if R&D and operating costs outrun available funding.

AIM ImmunoTech Inc. issued a stockholder letter from Chief Executive Officer Thomas Equels positioning its drug Ampligen as a potential complement to daraxonrasib following the U.S. Food and Drug Administration's recent approval of daraxonrasib for metastatic pancreatic cancer. The letter notes that a pivotal randomized study showed daraxonrasib achieved median overall survival of 13.2 months versus 6.7 months with standard chemotherapy, an improvement of 6.5 months, but that many patients on both treatments still experience disease progression and mortality. Ampligen, a TLR3 agonist designed to activate innate immunity and reshape the tumor microenvironment, has a different mechanism of action from daraxonrasib, which selectively inhibits RAS. In an analysis of patients with a blood neutrophil-to-lymphocyte ratio below 4.5 in a Dutch government-approved Named Patient Program, Ampligen as a monotherapy was linked to a median overall survival of 34.8 months versus 12.5 months in well-matched historical controls, an observed increase of 22.3 months. AIM also said its ongoing Phase 2 DURIPANC trial is evaluating Ampligen with AstraZeneca's durvalumab in patients whose pancreatic cancer was stable post-FOLFIRINOX, with topline results anticipated in Q1 2027 and a detailed overall survival analysis in Q3 2027.

Parnassus Growth Equity Fund added Revolution Medicines, Inc. as a new holding during the second quarter of 2026, citing promising late-stage clinical results for its lead pancreatic cancer drug candidate, daraxonrasib. In its Q2 2026 investor letter, the fund said daraxonrasib has delivered strong late-stage clinical results in pancreatic cancer, with data suggesting it could become a new standard of care and support significant commercial potential, alongside additional opportunities in other cancers over time. Revolution Medicines is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The stock closed at $204.86 per share on September 15, 2026, down 6.53% over the past month but up 358.00% over the past 52 weeks, giving the company a market capitalization of $43.91 billion. The fund itself returned 17.49% net of fees for the quarter, outperforming the Russell 1000 Growth Index's 16.74%, and returned 6.17% year-to-date against the index's 5.33%.

The FDA approved Revolution Medicines' Rasonque, also known as daraxonrasib, on August 26 for adults with metastatic pancreatic cancer who have already received prior treatment or cannot receive combination chemotherapy, Reuters reported. The once-daily pill is the first broad RAS-targeted medicine approved for pancreatic cancer, blocking several forms of the RAS protein that drives tumor growth in most cases of the disease, and it works without requiring a companion diagnostic test to identify a specific mutation. The approval rested on the Phase 3 RASolute 302 trial of 500 patients, in which those on Rasonque reached a median overall survival of 13.2 months versus 6.7 months on standard chemotherapy, nearly doubling survival. The FDA cleared the drug through its National Priority Voucher program, cutting the typical 10-to-12-month review to about a month after Revolution submitted the application on July 22. More than 2,000 patients had already received the drug through an expanded access program before formal approval, and Revolution set the wholesale price at $39,800 for a 30-day supply, with some commercially insured patients able to pay as little as $0 through copay assistance.

Revolution Medicines has secured the first-ever targeted therapy approval for metastatic pancreatic cancer, with its drug daraxonrasib cutting the risk of death by more than half in clinical data. The milestone marks a potential paradigm shift in oncology for the clinical-stage company, whose pipeline extends into lung cancer and other RAS-driven tumors. Revolution Medicines reported no revenue in FY 2025 and a net loss of around $1.1 billion as it expanded clinical trials, alongside a debt-to-equity ratio of approximately 0.1x and negative free cash flow of roughly $913.7 million. By contrast, Amgen posted FY 2025 revenue of nearly $36.7 billion, up about 9.9%, with net income of roughly $7.7 billion and a 21% net margin, though it faces Medicare price-setting for products like ENBREL and ongoing IRS tax disputes. A new partnership with Royalty Pharma provides funding for Revolution Medicines to pursue its pipeline without further diluting shareholders.

Revolution Medicines announced that the US FDA approved RASONQUE for adults with previously treated metastatic pancreatic adenocarcinoma, making it the first broad RAS targeted therapy for this cancer type. The approval marks the first approved product from the new class of RAS(ON) multi selective inhibitors, and the company also published Phase 1/2 data for RASONQUE in RAS mutant non small cell lung cancer in the New England Journal of Medicine. RASONQUE is being studied across multiple solid tumors, including non small cell lung cancer and colorectal cancer, positioning the drug for a multi indication franchise. However, the company still has no reported revenue and carries high operating expense guidance of US$1.6b to US$1.7b for 2026, so execution risk and cash use remain central to the story. A key near term signpost is the global Phase 3 RASolve 301 trial of RASONQUE in previously treated RAS mutant non small cell lung cancer, which is already under way and tests the drug against docetaxel.

The U.S. Food and Drug Administration approved Rasonque daraxonrasib, a once-daily pill from Revolution Medicines, for adults with metastatic pancreatic cancer who have already had chemotherapy, marking the first broad RAS-targeted medicine for this disease. In the RASolute 302 Phase 3 trial of 500 previously treated patients, the drug nearly doubled median overall survival to 13.2 months from 6.7 months on standard chemotherapy and cut the risk of death by 60%. The FDA cleared the drug in about 35 days after accepting the application, using the Commissioner's National Priority Voucher program, and more than 2,000 patients had already received it through an expanded access program. Revolution Medicines, which had no product revenue and held $3.9 billion in cash as of June 30, set the wholesale cost at $39,800 for a 30-day supply. RBC Capital Markets forecasts U.S. sales of about $28 million in the third quarter of 2026, roughly $148 million in the fourth quarter, and peak annual sales of an estimated $11.5 billion. Despite the landmark approval, RVMD shares stayed roughly flat near $211.70 on the day, as the stock had already risen 166% in 2026 ahead of the news. Investors now watch insurance coverage decisions, competition from Erasca, and progress in first-line pancreatic and lung cancer trials.

The U.S. Food and Drug Administration (FDA) on the 26th approved the pancreatic cancer treatment drug "Daraxonrasib," developed by the American biopharmaceutical company Revolution Medicines. It is a once-daily oral tablet that is expected to be a groundbreaking new drug that doubles patient survival time. Pancreatic cancer is difficult to detect and progresses rapidly. An FDA official noted that the approval "provides a new option for patients with cancers that were previously difficult to treat."

Revolution Medicines reported second quarter 2026 financial results and provided updates on its oncology pipeline. The company ended the quarter with $3.9 billion in cash and marketable securities, including $2.2 billion in gross proceeds from concurrent offerings of common stock and convertible notes completed in April 2026 and a $250 million second royalty tranche from Royalty Pharma received in May 2026. Research and development expenses rose to $395 million from $224 million a year earlier, while general and administrative expenses increased to $110 million from $41 million. Net loss for the quarter was $644 million, including a $151 million non-cash charge related to the fair value of warrants from the EQRx acquisition. The company updated its full-year 2026 GAAP operating expense guidance to between $2.1 billion and $2.2 billion, with stock-based compensation expected between $270 million and $290 million. Management highlighted the FDA acceptance of the New Drug Application for daraxonrasib in pancreatic cancer, the initiation of a phased review by the European Medicines Agency, and the expansion of its Expanded Access Program to over 2,000 patients across nearly all 50 U.S. states and Puerto Rico. New clinical data presented included an 82% objective response rate for zoldonrasib in combination with modified FOLFIRINOX in first-line RAS G12D pancreatic cancer and an 85% objective response rate for elironrasib in combination with pembrolizumab and chemotherapy in first-line RAS G12C non-small cell lung cancer.

BeOne Medicines Ltd. and Revolution Medicines, Inc. announced a collaboration in early August 2026 that includes BeOne funding a global Phase 3 trial for Revolution Medicines' RAS(ON) inhibitors. The deal combines BeOne's oncology assets with Revolution's four clinical RAS(ON) inhibitors and grants BeOne exclusive development and commercialization rights in select Asian markets. This arrangement offloads near-term late-stage costs for Revolution Medicines, which reported a net loss of US$644.37 million for the second quarter of 2026 and US$1,098.19 million over six months. The core catalyst remains regulatory progress and eventual commercialization of daraxonrasib, with ongoing large-scale trial execution and spending still posing significant risk.

Shares of Revolution Medicines have surged more than 134% this year, drawing attention after billionaire Stanley Druckenmiller's Duquesne Family Office bought 316,000 shares in the first quarter. The clinical-stage biotech's lead drug Daraxonrasib doubled median survival to 13.2 months versus 6.7 months for standard chemotherapy in a phase III pancreatic cancer trial, earning FDA Breakthrough Therapy Designation. The company holds $1.9 billion in cash plus $2.1 billion from recent financing to support its pipeline, which targets broad RAS mutations across pancreatic, lung, and colorectal cancers. Revolution is nearing completion of its New Drug Application to the FDA, and the European Medicines Agency initiated an accelerated review this month, with analysts projecting $7 billion in annual sales for Daraxonrasib.

Shares of Revolution Medicines have gained 132% this year, easily outpacing the returns of leading pharmaceutical companies such as Eli Lilly, Johnson & Johnson, and AbbVie. The clinical-stage drugmaker is developing drugs that target cancer-driving proteins once considered undruggable, and its leading candidate daraxonrasib showed a median overall survival of 13.2 months versus 6.7 months for cytotoxic chemotherapy in a head-to-head metastatic pancreatic cancer study. Despite the promise, the company is worth $39 billion with no products on the market and consistent unprofitability, making the valuation look frothy and the stock risky at current levels. The author suggests that a major clinical or regulatory setback could sink the share price and would only consider buying on a significant dip.

The FDA accepted Revolution Medicines' New Drug Application for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, and granted it priority review after the Phase 3 RASolute 302 trial in previously treated metastatic pancreatic ductal adenocarcinoma met all primary and key secondary endpoints. The same data earned daraxonrasib priority pathways on both sides of the Atlantic, including the FDA Commissioner's National Priority Voucher pilot program and high-priority status under the EMA's Cancer Medicines Pathfinder project. The acceptance sharpens the near-term catalyst around a first approval, while upcoming data for zoldonrasib combinations in first-line pancreatic cancer could frame daraxonrasib as part of a broader RAS(ON) franchise. However, high 2026 operating expense guidance and reliance on external capital remain key risks.

Hagens Berman is investigating claims in a securities class action against Erasca, Inc., alleging the company misled investors about its lead oncology candidate ERAS-0015. The litigation claims Erasca used flawed preclinical comparisons to tout superiority over Revolution Medicines' RMC-6236, concealed intellectual property disputes that exposed it to patent infringement and trade secret misappropriation claims, and downplayed safety risks that later included a patient death. On April 27–28, 2026, disclosures of a legal challenge from Revolution Medicines and adverse clinical data triggered a sharp stock decline that wiped out over $2.8 billion in market capitalization. The class period runs from January 14, 2025, to April 26, 2026, and the lead plaintiff deadline is August 10, 2026.

Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed against Erasca, Inc. in the United States District Court for the Southern District of California. The lawsuit covers purchasers of Erasca common stock between January 14, 2025 and April 26, 2026, with a lead plaintiff deadline of August 10, 2026. The complaint alleges that defendants made false and misleading statements regarding ERAS-0015, including that its preclinical data relied on improper comparisons to Revolution Medicines and risked patent and trade secret violations. On April 28, 2026, Erasca disclosed a letter from Revolution Medicines alleging patent infringement and trade secret misappropriation, causing the stock to drop $9.25 per share, or approximately 48%, from $19.15 to $9.90. Investors who suffered losses can contact the firm at investigations@bespc.com or (212) 355-4648.

Glancy Prongay Wolke & Rotter LLP reminds Erasca, Inc. shareholders of the August 10, 2026 deadline to seek lead plaintiff status in a class action covering purchases of Erasca common stock between January 14, 2025 and April 26, 2026. The lawsuit alleges the company made misleading statements and failed to disclose that its drug candidate ERAS-0015 involved improper preclinical data comparisons to Revolution Medicines and risked patent and trade secret violations. On April 27, 2026, Erasca disclosed a letter from Revolution Medicines alleging patent infringement and trade secret misappropriation, causing the stock to drop 10.9% to $19.15 per share. After market hours that day, Erasca reported a patient death in a Phase 1 trial of ERAS-0015, sending shares down an additional 48.3% to $9.90 on April 28, 2026.

A new competitive landscape report from DelveInsight reveals that more than 80 active pharmaceutical companies are developing over 90 pipeline molecular glues, with approximately 7 therapies in late-stage development and 15 in mid- or early-stage trials. Key players include Revolution Medicines, Gluetacs Therapeutics, Captor Therapeutics, Nurix Therapeutics, Monte Rosa Therapeutics, and Neomorph, among others, evaluating candidates such as Daraxonrasib, GT919, CT-01, and NEO-811. The report highlights notable mechanisms of action including RAS(ON) inhibition, GSPT1 degradation, and c-Myc degradation, and covers recent milestones like the FDA’s Breakthrough Therapy Designation for Daraxonrasib and the first patient dosing in Degron Therapeutics’ Phase 1 trial of DEG6498. Approved molecular glues POMALYST and REVLIMID from Bristol Myers Squibb are also profiled, underscoring the class’s established role in multiple myeloma and other hematologic malignancies.

Pomerantz LLP has filed a class action lawsuit against Erasca, Inc. concerning potential securities fraud or unlawful business practices. Investors who purchased or acquired Erasca securities during the Class Period have until August 10, 2026, to seek appointment as Lead Plaintiff. The complaint follows Erasca's April 27, 2026, disclosure of a letter from Revolution Medicines alleging patent infringement and trade secret misappropriation related to ERAS-0015, which caused Erasca's stock to fall 10.71% to $19.50 per share. After market hours that same day, Erasca reported preliminary Phase 1 data for ERAS-0015, including a patient death, and clarified that comparisons to other product candidates were based on cross-study analyses, leading to a further 48.3% drop to $9.90 per share on April 28, 2026.

Hagens Berman is actively investigating claims in a securities class action against Erasca, Inc. The litigation alleges that Erasca and its senior executives misled investors about the competitive advantage, safety profile, and intellectual property surrounding its lead oncology candidate, ERAS-0015, during the class period from January 14, 2025 to April 26, 2026. The complaint claims the company used flawed preclinical comparisons to assert superiority over Revolution Medicines' RMC-6236, concealed patent infringement and trade secret misappropriation risks, and downplayed safety concerns that later included a patient death. On April 27–28, 2026, disclosures of a legal challenge from Revolution Medicines and adverse clinical data triggered a sharp stock decline that wiped out over $2.8 billion in market capitalization. Investors who purchased Erasca common stock during the class period have until August 10, 2026 to seek appointment as lead plaintiff.

Revolution Medicines has seen its stock skyrocket 125% in 2026, and billionaire Stanley Druckenmiller's Duquesne Family Office bought 316,000 shares in the first quarter. The stake was worth $30.6 million at the time of the 13F filing and has since grown to $56.6 million, representing 1% to 2% of the firm's equity portfolio. The company's flagship treatment, Daraxonrasib, has not yet generated revenue or received FDA approval, but positive Phase 3 trial results showing nearly doubled survival rates for metastatic pancreatic cancer patients led to Breakthrough Therapy and Orphan Drug designations. Revolution Medicines is nearing completion of its New Drug Application to the FDA, and the European Medicines Agency launched an accelerated review this month, setting the stage for a potential global launch.

Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Erasca, Inc. securities between January 14, 2025 and April 26, 2026. The lawsuit alleges that Erasca failed to disclose it was at risk of violating patent and trade secret protections, specifically that ERAS-0015’s preclinical data was based on improper comparisons to Revolution Medicines and placed Erasca at risk of infringement. On April 27, 2026, Erasca disclosed it had received a letter from RevMed’s legal counsel alleging patent infringement and trade secret misappropriation, causing Erasca’s stock price to fall from $21.49 per share on April 24, 2026, to $19.15 per share on April 27, 2026. Shareholders who wish to serve as lead plaintiff must submit their papers to the court by August 10, 2026.

Erasca faces a securities class action after its stock dropped $9.25, or 48%, following disclosures that Revolution Medicines accused Erasca of patent infringement concerning its pan-RAS molecular glue ERAS-0015 and that a patient died one month after receiving the treatment. The lawsuit, filed by Hagens Berman, seeks to represent investors who purchased Erasca common stock between January 14, 2025 and April 26, 2026. The complaint alleges Erasca misled investors by improperly comparing ERAS-0015 to Revolution Medicines' RMC-6236 and by touting intellectual property protection that exposed the company to disputes. On April 27, 2026, Erasca disclosed the patent challenge and the patient death, wiping out over $2.8 billion in market capitalization the next day. The lead plaintiff deadline is August 10, 2026.

Kirby McInerney LLP reminds Erasca, Inc. investors of the August 10, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. The lawsuit, filed on behalf of investors who purchased securities between January 14, 2025 and April 26, 2026, alleges that Erasca and its executives made false and misleading statements about its lead oncology drug candidate, ERAS-0015, including improper comparisons to Revolution Medicines' competing drug candidate, RMC-6236, while failing to disclose patent and trade secret risks. On April 27, 2026, Erasca disclosed a letter from RevMed alleging patent infringement and trade secret misappropriation, causing shares to fall 11% from $21.49 to $19.15. A subsequent disclosure of a patient death in a Phase 1 trial and limitations on cross-study comparisons sent shares down an additional 48% to $9.90. Investors who purchased Erasca securities may contact the firm to discuss their rights.

Revolution Medicines announced positive results from two Phase 1/2 trials of zoldonrasib-based combinations in RAS G12D metastatic pancreatic ductal adenocarcinoma. In the RMC-GI-102 trial, zoldonrasib plus modified FOLFIRINOX achieved an 82% objective response rate and 96% disease control rate, while the combination with gemcitabine plus nab-paclitaxel showed 61% and 90%, respectively. The RMC-9805-001 trial of zoldonrasib plus daraxonrasib in previously treated patients demonstrated a 50% objective response rate and 97% disease control rate in the second-line cohort, with median progression-free survival of 9.6 months. In the third-line and later cohort, the objective response rate was 47% and disease control rate was 90%, with median overall survival of 10.5 months. Safety profiles were manageable, with Grade 3 or higher treatment-related adverse events occurring in 61% and 80% of patients in the chemotherapy combination arms, and 35% in the zoldonrasib-daraxonrasib arm.

Revolution Medicines has seen its stock price soar nearly 140% in 2026 following positive late-stage clinical trial results for its lead candidate daraxonrasib in previously treated metastatic pancreatic cancer. The phase 3 trial showed a survival rate of 13.2 months for daraxonrasib compared to 6.7 months for standard chemotherapy, and the company plans to submit these final results for regulatory review. Revolution is also advancing another candidate, zoldonrasib, in phase 3 trials for the same indication, while daraxonrasib is in phase 3 for non-small cell lung cancer and zoldonrasib is entering phase 3 as a combination therapy. The company remains pre-revenue, with a recent quarterly loss of more than $453 million, but holds $1.9 billion in cash and $2.1 billion in net proceeds from financing to support ongoing research and development. Despite the stock's triple-digit gain, some analysts view Revolution as a compelling buy for growth investors due to its novel tri-complex inhibitor platform targeting RAS proteins and its proximity to potential product approval.

Tango Therapeutics is emerging as a key test of precision oncology's value in 2026, centered on MTAP-deleted cancers and synthetic lethality. Its lead asset vopimetostat, an MTA-cooperative PRMT5 inhibitor, is being combined with Revolution Medicines' daraxonrasib and zoldonrasib, as well as Erasca's pan-RAS molecular glue ERAS-0015, in MTAP-deleted, RAS-mutant pancreatic cancer. An early signal from the vopimetostat-daraxonrasib arm showed a 92% objective response rate, 100% disease control rate, and 90% six-month progression-free survival rate among 12 evaluable patients, with plans to advance into late-stage development. Vopimetostat is also in monotherapy studies for MTAP-deleted lung cancer, while brain-penetrant TNG456 is in a phase I/II trial for MTAP-deleted solid tumors including glioblastoma, with data expected in 2026. The stock carries a Zacks Rank #3 (Hold) and a Momentum Score of B, though value and growth scores remain weak.

Pomerantz LLP has filed a class action lawsuit against Erasca, Inc. concerning potential securities fraud or unlawful business practices. Investors who purchased or acquired Erasca securities during the Class Period have until August 10, 2026, to seek appointment as Lead Plaintiff. The lawsuit follows disclosures on April 27, 2026, that Revolution Medicines alleged patent infringement and trade secret misappropriation related to Erasca's ERAS-0015, causing Erasca's stock to fall 10.71% to $19.50 per share. After market hours that same day, Erasca reported preliminary Phase 1 data for ERAS-0015, including a patient death classified as a Grade 3 treatment-related adverse event of pneumonitis that progressed to Grade 5, and acknowledged that comparisons with other product candidates were based on cross-study analyses and not head-to-head trials, leading to a further 48.3% drop to $9.90 per share on April 28, 2026.

Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed against Erasca, Inc. in the United States District Court for the Southern District of California on behalf of purchasers of Erasca common stock between January 14, 2025 and April 26, 2026. The lawsuit alleges that the company made false and misleading statements and failed to disclose that ERAS-0015’s preclinical data was based on improper comparisons to Revolution Medicines, Inc., placing Erasca at risk of violating patent and trade secret protections. On April 28, 2026, Erasca disclosed a letter from Revolution Medicines alleging patent infringement and trade secret misappropriation related to ERAS-0015, causing the stock to drop 48 percent from $19.15 to $9.90 per share. Investors have until August 10, 2026 to seek lead plaintiff appointment.

Moore Law PLLC is investigating potential claims against officers and directors of Erasca, Inc. over allegations that the company made false or misleading statements about its drug candidate ERAS-0015. The investigation concerns claims that positive statements about ERAS-0015 lacked a reasonable basis, as preclinical data was allegedly based on improper comparisons to Revolution Medicines and placed Erasca at risk of patent and trade secret violations. On April 27, 2026, Erasca disclosed a letter from Revolution Medicines alleging patent infringement and trade secret misappropriation, and demanding an end to deceptive comparative statements. Following the news, Erasca’s stock fell from $21.49 per share on April 24 to $19.15 per share on April 27. Shareholders may be able to seek monetary damages and corporate governance reforms on a contingency fee basis.

Revolution Medicines announced it will present clinical data from its RAS(ON) inhibitor pipeline at the 2026 ESMO Gastrointestinal Cancers Congress in Munich from July 1 to 4. The presentations include two oral reports from Phase 1/2 trials of zoldonrasib, an oral RAS(ON) G12D-selective covalent inhibitor, in combination regimens for metastatic RAS G12D pancreatic ductal adenocarcinoma. One oral presentation covers zoldonrasib plus chemotherapy in the first-line setting, while the other covers zoldonrasib plus daraxonrasib, the company's oral RAS(ON) multi-selective inhibitor, in patients who had received one or more prior lines of therapy. Two Phase 3 trials-in-progress posters will also be shown: RASolute 303, evaluating daraxonrasib as monotherapy or in combination with gemcitabine and nab-paclitaxel versus standard of care in first-line metastatic PDAC, and RASolute 304, evaluating adjuvant daraxonrasib in patients with resected PDAC who completed perioperative chemotherapy.

Revolution Medicines has started treating patients in the phase III RASolute 305 study, evaluating its investigational oral RAS(ON) G12D-selective inhibitor zoldonrasib in combination with chemotherapy for first-line metastatic RAS G12D pancreatic ductal adenocarcinoma. The global late-stage trial will compare zoldonrasib plus investigator-selected standard-of-care chemotherapy against placebo plus chemotherapy, with co-primary endpoints of progression-free survival and overall survival. Zoldonrasib targets the RAS G12D mutation, which is present in about 40% of PDAC tumors and currently has no approved targeted therapies. Revolution Medicines is also advancing its lead candidate daraxonrasib in the phase III RASolute 303 study for first-line metastatic PDAC, and recently reported positive top-line data from the phase III RASolute 302 study in previously treated patients. Year to date, Revolution Medicines shares have surged 112.9%.

Berger Montague has filed a securities fraud class action lawsuit against Erasca, Inc. on behalf of investors who purchased or acquired Erasca common stock between January 14, 2025 and April 26, 2026. The suit alleges that the company misrepresented its lead drug candidate ERAS-0015 as a potential best-in-class therapy with superior preclinical results compared to Revolution Medicines' RMC-6236. On April 27, 2026, Erasca disclosed accusations of patent infringement and trade secret misappropriation from Revolution Medicines, and reported preliminary clinical data including a patient death while admitting its comparisons relied on cross-study analyses rather than head-to-head trials. Erasca's stock fell more than 45% on the news. Investors have until August 10, 2026 to seek appointment as lead plaintiff.